Novartis and Subsidiaries Settle FCPA Cases for $346M, Avoiding a Monitor Despite Recidivism

Wednesday, July 8, 2020

Niki Sprinzen was quoted in an Anti-Corruption Report discussing the settlement agreement Novartis, a Swiss pharmaceutical company, reached with the U.S. DOJ and the SEC to settle FCPA charges. Ultimately, “a company’s enforcement history and resolutions with other enforcement agencies play into the form and size of a resolution,” said Niki.

To read more of this article, click here. (subscription required)

Share on LinkedIn


Related Practice Areas

Keep up-to-date with the latest news from Cozen O'Connor

Enter your City or Zip.

Probably shouldn't change this:
Sign up to receive alerts, publications, and event / webinar invites.

By submitting your contact information, you are giving Cozen O'Connor consent to contact you via email.